Runben Biotechnology released its performance for the first half of the year, with a net profit attributable to the parent company of 188 million yuan, an increase of 4.16%

Runben Biotechnology released its semi-annual report for 2025, with operating revenue of 895 million yuan, a year-on-year increase of 20.31%; net profit attributable to the parent company of 188 million yuan, a year-on-year increase of 4.16%. The net profit excluding non-recurring gains and losses was 177 million yuan, a year-on-year increase of 0.86%. The basic earnings per share were 0.46 yuan. The company launched more sunscreen products, expanded offline channels, and plans to distribute a cash dividend of 2.00 yuan for every 10 shares to all shareholders